BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced its third quarter financial results for the period ended September 30, 2015.
Recent and Third Quarter Developments
- Revenues, net for the company’s prescription prenatal vitamin business increased to approximately $5.2 million for the third quarter of 2015 compared with approximately $4.2 million for the third quarter of 2014.
- Net loss was approximately $19.5 million for the third quarter of 2015, compared with approximately $17.8 million for the third quarter of 2014, reflecting the costs of two phase 3 clinical trials for the company’s novel hormone therapy drug candidates.
- Completed last patient visit in the Rejoice Trial, a phase 3 clinical trial of TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
- Completed patient enrollment in the Replenish Trial, a phase 3 clinical trial of TX-001HR, a combination estradiol and progesterone drug candidate, for the treatment of moderate to severe vasomotor symptoms due to menopause.
- Ended the quarter with approximately $81.1 million in cash and no debt.
- Grew the company’s intellectual property portfolio to a current total of 111 patent filings, including 61 international filings, with two allowed and 13 issued U.S. patents.
- Supported scientific abstracts and presentations at the annual meeting of the North American Menopause Society.
- Continued to develop relationships with key medical, pharmacy, patient and industry organizations.
“As we pursue our mission to address women’s health needs, we believe that there is a unique confluence of factors evolving on the scientific, regulatory, legislative and commercial fronts that will help us to make significant progress toward delivering on our vision and strategy,” said TherapeuticsMD CEO Robert G. Finizio. “We continue to execute both commercially and in R&D, including completion of enrollment in our Replenish Trial of TX-001HR, our combination estradiol and progesterone drug candidate for treatment of moderate to severe vasomotor symptoms due to menopause. We also expect topline data from our Rejoice Trial of TX-004HR for dyspareunia associated with VVA by the end of this year. The market need for our products is large and growing, and we are building key alliances with healthcare providers, women’s health advocates and industry organizations.”
Third Quarter Financial Results Summary
Revenues, net for the third quarter of 2015 increased by 24 percent to approximately $5.2 million compared with revenues, net of approximately $4.2 million for the prior year’s quarter. Revenue growth during the third quarter was primarily driven by increased number of units sold, product mix, and average net sales price of the company’s prenatal vitamin products.
Cost of goods sold increased to approximately $1.2 million for the three months ended September 30, 2015, compared with approximately $1.1 million in the prior year’s quarter.
Total operating expenses for the third quarter of 2015 included research and development (R&D) expenses and sales, general and administration (SG&A). R&D expenses for the third quarter of 2015 were approximately $16.4 million compared with approximately $14.9 million for the prior year’s quarter. The increase in R&D expense was primarily due to an increase in scale-up and manufacturing activities for the company’s phase 3 drugs in development, which was partially offset by lower clinical trial costs. SG&A expenses for the third quarter of 2015 were approximately $7.0 million compared with approximately $6.0 million for the third quarter of 2014, primarily as a result of increases in human resources costs and professional fees, which were partially offset by a decrease in marketing costs.
Non-operating income remained insignificant for the third quarter of 2015 and 2014 and included miscellaneous and interest income for both periods.
Net loss for the third quarter of 2015 was approximately $19.5 million, or $0.11 per basic and diluted share, compared with approximately $17.8 million, or $0.12 per basic and diluted share, for the third quarter of 2014.
At September 30, 2015, TherapeuticsMD had cash on hand of approximately $81.1 million, compared with approximately $51.4 million at December 31, 2014.
Conference Call Today
As previously announced, TherapeuticsMD will host a conference call today to discuss these financial results and provide a business update. Details for the call are:
Date: Wednesday, November 4, 2015
Time: 4:30 p.m. EST
Telephone Access (US): 866-665-9531
Telephone Access (International): 724-987-6977
Access Code for All Callers: 61714687
Additionally, a live webcast can be accessed on the company’s website, www.therapeuticsmd.com, on the “Home Page” or under the “Investor” section.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company’s clinical development pipeline includes two phase 3 products. The company also manufactures and distributes branded and generic prescription prenatal vitamins as well as over-the-counter vitamins under the vitaMedMD® and BocaGreenMD® brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com, www.vitamedmdrx.com and www.bocagreenmd.com.
This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors” in the company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize its hormone therapy drug candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company’s clinical trials; the potential of adverse side effects or other safety risks that could preclude the approval of the company’s hormone therapy drug candidates; the company’s reliance on third parties to conduct its clinical trials, research and development and manufacturing; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership. PDF copies of the company’s historical press releases and financial tables can be viewed and downloaded at its website: www.therapeuticsmd.com/pressreleases.aspx.
|THERAPEUTICSMD, INC. AND SUBSIDIARIES|
|CONSOLIDATED BALANCE SHEETS|
|September 30, 2015||December 31, 2014|
|Accounts receivable, net of allowance for doubtful accounts|
|of $96,916 and $59,753, respectively||3,666,586||2,154,217|
|Other current assets||2,120,805||1,537,407|
|Total current assets||87,781,438||56,235,344|
|Fixed assets, net||56,748||63,293|
|Intangible assets, net||1,324,284||1,228,588|
|Total other assets||2,621,335||2,780,851|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Other current liabilities||6,386,777||3,840,639|
|Total current liabilities||11,688,402||10,690,381|
|Commitments and Contingencies|
|Preferred stock - par value $0.001; 10,000,000 shares authorized;|
|no shares issued and outstanding||-||-|
|Common stock - par value $0.001; 350,000,000 and 250,000,000 shares|
|authorized; 177,787,927 and 156,097,019 issued and outstanding, respectively||177,788||156,097|
|Additional paid-in capital||279,723,640||182,982,846|
|Total stockholders' equity||77,557,245||48,389,107|
|Total liabilities and stockholders' equity||$||90,459,521||$||59,079,488|
|THERAPEUTICSMD, INC. AND SUBSIDIARIES|
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Cost of goods sold||1,193,965||1,068,605||3,270,695||2,792,268|
|Sales, general, and administration||7,060,944||6,043,354||20,089,998||16,610,015|
|Research and development||16,421,753||14,909,430||58,789,302||29,052,149|
|Depreciation and amortization||16,548||12,747||44,400||39,909|
|Total operating expenses||23,499,245||20,965,531||78,923,700||45,702,073|
|Other income (expense):|
|Total other income (expense)||30,390||15,624||86,890||(188,860||)|
|Loss before income taxes||(19,472,645||)||(17,832,251||)||(67,594,347||)||(37,914,629||)|
|Provision for income taxes||-||-||-||-|
|Loss per share, basic and diluted:|
|Net loss per share, basic and diluted||$||(0.11||)||$||(0.12||)||$||(0.39||)||$||(0.26||)|
|Weighted average number of common|
|shares outstanding, basic and diluted||177,206,168||152,200,455||171,589,595||147,594,810|
|THERAPEUTICSMD, INC. AND SUBSIDIARIES|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Nine Months Ended|
|September 30, 2015||September 30, 2014|
|CASH FLOWS FROM OPERATING ACTIVITIES|
|Adjustments to reconcile net loss to net cash used in|
|Amortization of intangible assets||22,296||17,196|
|Provision for doubtful accounts||37,163||2,594|
|Amortization of deferred financing costs||-||260,027|
|Changes in operating assets and liabilities:|
|Other current assets||(621,923||)||197,569|
|Other current liabilities||2,546,138||909,890|
|Long term accrued expenses||1,213,874||-|
|Net cash used in operating activities||(62,434,546||)||(30,235,734||)|
|CASH FLOWS FROM INVESTING ACTIVITIES|
|Purchase of property and equipment||(15,559||)||(30,962||)|
|Net cash used in investing activities||(133,551||)||(224,311||)|
|CASH FLOWS FROM FINANCING ACTIVITIES|
|Proceeds from sale of common stock, net of costs||91,374,649||42,771,353|
|Proceeds from exercise of options||589,829||315,546|
|Proceeds from exercise of warrants||366,000||181,000|
|Net cash provided by financing activities||92,330,478||43,267,899|
|Increase in cash||29,762,381||12,807,854|
|Cash, beginning of period||51,361,607||54,191,260|
|Cash, end of period||$||81,123,988||$||66,999,114|